Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714982 · ClinicalTrials.gov registry record · NA
Impact of E-cigarette Device Warnings
A NA study of Vaping Behaviors, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1,369
- Enrollment target
- 1
- Study location
NCT05714982: Completed NA study of Vaping Behaviors, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT05714982 is a NA study of Vaping Behaviors that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 1,369 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714982, a NA study of Vaping Behaviors, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,369 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this randomized clinical trial is to determine whether e-cigarette warnings increase intentions to quit vaping without the unintended consequence of pushing users toward smoking. This trial addresses these issues by evaluating the impact of e-cigarette warnings by randomly assigning vapers to have their devices and refills labeled with control messages, text warnings, or pictorial warnings. Participants will be US adult (ages 21+) vapers. The trial expects \~1,200 participants to complete Visits 1, 3, and 5.
Primary Outcome
The primary outcome is vaping quit intentions measured by 3 survey items at 5 time points: post-labeling (Visit 1) and at 1, 2, 3, and 4 weeks (Visits 2-5). Study investigators will average the items to create a score for each time point and take an average across the time points. The range for this measure will be 1 to 5, with higher values indicating higher quit intentions.
Conditions Studied
Interventions
- OTHER Label with text health warning
- OTHER Label with pictorial health warning
- OTHER Label with neutral statements about vaping
Study Locations (1)
California
- Ewald & Wasserman Research Consultants, LLC - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,369 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2024-07-23 |
| Phase | NA |
What the finished NCT05714982 record still lists
NCT05714982 is an interventional study that assigns participants to a tested intervention. Its 1,369 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 1 condition, with Vaping Behaviors appearing as the primary indexed condition, and to 3 interventions - of which Label with text health warning is the first listed.
NCT05714982 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05714982 about?
NCT05714982 is a clinical study titled "Impact of E-cigarette Device Warnings". The purpose of this randomized clinical trial is to determine whether e-cigarette warnings increase intentions to quit vaping without the unintended consequence of pushing users toward smoking. This trial addresses these issues by evaluating the impact of e-cigarette warnings by randomly assigning v...
What is the current status of trial NCT05714982?
This trial is currently completed. It is a NA study. The enrollment target is 1,369 participants. The study started on 2023-02-23. Estimated completion is 2024-07-23.
What conditions does trial NCT05714982 study?
This clinical trial studies the following conditions: Vaping Behaviors.
What interventions are being tested in trial NCT05714982?
The interventions under investigation include: Label with text health warning (OTHER), Label with pictorial health warning (OTHER), Label with neutral statements about vaping (OTHER).
Who is sponsoring clinical trial NCT05714982?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714982 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaping Behaviors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05714982's enrollment target sits among peer trials
1,369 73rd of 2000 higher than 1,928 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI